GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » ROIC %

Basilea Pharmaceutica (LTS:0QNA) ROIC % : -26.67% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Basilea Pharmaceutica's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -26.67%.

As of today (2024-05-15), Basilea Pharmaceutica's WACC % is 4.51%. Basilea Pharmaceutica's ROIC % is 17.22% (calculated using TTM income statement data). Basilea Pharmaceutica generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Basilea Pharmaceutica ROIC % Historical Data

The historical data trend for Basilea Pharmaceutica's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica ROIC % Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.35 -27.38 2.73 13.72 17.98

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.92 -10.25 38.21 55.88 -26.67

Competitive Comparison of Basilea Pharmaceutica's ROIC %

For the Biotechnology subindustry, Basilea Pharmaceutica's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's ROIC % distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's ROIC % falls into.



Basilea Pharmaceutica ROIC % Calculation

Basilea Pharmaceutica's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=21.908 * ( 1 - 0.1% )/( (135.957 + 107.542)/ 2 )
=21.886092/121.7495
=17.98 %

where

Basilea Pharmaceutica's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-32.75 * ( 1 - 0.08% )/( (137.878 + 107.542)/ 2 )
=-32.7238/122.71
=-26.67 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Basilea Pharmaceutica  (LTS:0QNA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Basilea Pharmaceutica's WACC % is 4.51%. Basilea Pharmaceutica's ROIC % is 17.22% (calculated using TTM income statement data). Basilea Pharmaceutica generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Basilea Pharmaceutica earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Basilea Pharmaceutica ROIC % Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica (LTS:0QNA) Business Description

Traded in Other Exchanges
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines